24 August 2017

Bone Therapeutics Notice of Half Year 2017 Results

 

Results to be announced on 31 August 2017

Gosselies, Belgium, 24 August 2017, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, will announce its half year results for the six-month period ended 30 June 2017 on Thursday 31 August at 7am CEST.

The Company will host a conference call and Q&A at 11:00 CEST / 10:00 BST. The call will be conducted in English and a replay will be available for 30 days.

To access the conference call, please dial one of the appropriate numbers below quoting the conference ID:

BE: +32 (0) 81 70 00 61

FR: +33 (0) 176 74 24 28

US: +1 (866) 966 9439

Standard International Dial-In: +44 (0) 1452 555 566

Conference ID: 75560121

The presentation will be made available on the Investors section of the Bone Therapeutics website shortly before the call and can be accessed at: http://www.bonetherapeutics.com/en/investors/presentations.

 

About Bone Therapeutics

Bone Therapeutics is a leading cell therapy company addressing high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy products in clinical development across a number of disease areas targeting markets with large unmet medical needs and limited innovation.

Our technology is based on a unique, proprietary approach to bone regeneration which turns undifferentiated stem cells into “osteoblastic”, or bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery.

Our primary clinical focus is ALLOB®, an allogeneic “off-the-shelf” cell therapy product derived from stem cells of healthy donors, which is in Phase II studies for the treatment of delayed-union fractures and spinal fusion. The Company also has an autologous bone cell therapy product, PREOB®, obtained from patient’s own bone marrow and currently in Phase III development for osteonecrosis and non-union fractures.

Bone Therapeutics’ cell therapy products are manufactured to the highest GMP standards and are protected by a rich IP estate covering nine patent families. Further information is available at: www.bonetherapeutics.com.

 

For further information, please contact:

Bone Therapeutics SA

Tel: +32 (0)2 529 59 90

Thomas Lienard, Chief Executive Officer

Wim Goemaere, Chief Financial Officer

investorrelations@bonetherapeutics.com

For Belgium and International Media Enquiries:

Consilium Strategic Communications

Amber Fennell, Jessica Hodgson and Hendrik Thys

 

Tel: +44 (0) 20 3709 5701

bonetherapeutics@consilium-comms.com

For French Media and Investor Enquiries:

NewCap Investor Relations

& Financial Communications

Pierre Laurent, Louis-Victor Delouvrier and Nicolas Merigeau

 

Tel: + 33 (0)1 44 71 94 94 

bone@newcap.eu 

To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled start timing.


Back to previous page